25 Recruiting Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by Study Phase
Top Interventions for Clinical Stage III Cutaneous Melanoma AJCC v8
Related Conditions
Top Recruiting Clinical Stage III Cutaneous Melanoma AJCC v8 Studies
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
📍 Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
View Study & Checklist ➔Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
View Study & Checklist ➔Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View Study & Checklist ➔Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
View Study & Checklist ➔Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
📍 Moffitt Cancer Center - McKinley Campus — Tampa, Florida
View Study & Checklist ➔Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View Study & Checklist ➔Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
📍 UC San Diego Moores Cancer Center — La Jolla, California
View Study & Checklist ➔